MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Inogen Operating Income 2011-2026 | INGN
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Inogen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -42.5 M | -109 M | -85.2 M | 9.24 M | -12 M | 19.8 M | 37.9 M | 27.6 M | 22.9 M | 15.1 M | 10.5 M | 4.46 M | 829 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.9 M | -109 M | -7.76 M |
Quarterly Operating Income Inogen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.12 M | -6.13 M | -7.66 M | - | -7.79 M | -7.06 M | -16.3 M | - | -46.7 M | -11.8 M | -21.9 M | - | -10.3 M | -2.88 M | -13.6 M | - | 6.37 M | 11.7 M | -2.13 M | - | -1.97 M | -2.35 M | -2.18 M | - | 8.11 M | 12.1 M | 4.86 M | - | 10.4 M | 14 M | 8.7 M | - | 8.33 M | 8.5 M | 5.57 M | - | 5.4 M | 8.02 M | 3.28 M | - | 3.71 M | 5.34 M | 2.52 M | - | 3.57 M | 3.96 M | 1.55 M | - | 886 K | 2.39 M | 633 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14 M | -46.7 M | -715 K |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
-3.29 M | $ 33.22 | 1.87 % | $ 1.47 B |  USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Aziyo Biologics
AZYO
|
-30.5 M | - | 1.37 % | $ 20.5 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 7.01 | 2.04 % | $ 503 M |  Israel |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.76 | -1.7 % | $ 130 M | USA |
 |
Alphatec Holdings
ATEC
|
-136 M | $ 13.29 | 1.41 % | $ 1.9 B | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 255.19 | -12.51 % | $ 7.2 B | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 36.35 | -3.09 % | $ 5.42 K | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
CONMED Corporation
CNMD
|
200 M | $ 41.59 | -0.28 % | $ 1.28 B | USA |
 |
Boston Scientific Corporation
BSX
|
2.6 B | $ 74.77 | 0.88 % | $ 110 B | USA |
 |
Abbott Laboratories
ABT
|
6.82 B | $ 112.22 | 0.66 % | $ 195 B | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 4.8 | 0.63 % | $ 179 M |  France |
 |
Delcath Systems
DCTH
|
-12.4 M | $ 9.25 | 1.43 % | $ 264 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 13.44 | 3.07 % | $ 363 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 24.2 | 3.82 % | $ 205 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
InMode Ltd.
INMD
|
113 M | $ 14.36 | 0.38 % | $ 1.14 B | Israel |
 |
IRadimed Corporation
IRMD
|
22 M | $ 99.81 | -0.03 % | $ 1.26 B | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Integer Holdings Corporation
ITGR
|
208 M | $ 85.46 | 0.23 % | $ 2.87 B | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Penumbra
PEN
|
9.28 M | $ 339.82 | 0.32 % | $ 13.1 B | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.55 | 0.05 % | $ 122 M | USA |
 |
Pulmonx Corporation
LUNG
|
-57.7 M | $ 1.47 | 3.17 % | $ 57.5 M | USA |
 |
Globus Medical
GMED
|
166 M | $ 87.89 | 0.76 % | $ 11.9 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 11.29 | 4.46 % | $ 869 M | USA |
 |
Myomo
MYO
|
-10.7 M | $ 0.82 | 0.41 % | $ 5.78 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-50 M | $ 75.22 | 2.28 % | $ 2.12 B |  Costa-rica |